Ma ke ao holoʻokoʻa, ke ulu mau nei ka R&D e pili ana i ka maʻi kanesa o ka umauma ma nā ʻano āpau i ka wikiwiki nui i nā makahiki i hala aku nei a e hoʻomau ʻia i nā makahiki e hiki mai ana. 'O ka ma'i 'a'ai ma'amau ka lua o ka ma'i 'a'ai ma'amau o ka honua a 'o ka ma'i 'a'ai ma'amau i nā wāhine ma ka honua holo'oko'a.

ʻO ke kanaka epidermal growth factor receptor 2-positive (HER2+) ka maʻi ʻaʻai umauma ma kahi o 20% o nā hihia maʻi maʻi umauma a ua pili ka mōʻaukala me ka wānana maikaʻi ʻole i ka loaʻa ʻole o nā lāʻau lapaʻau kūpono. ʻO ka ʻike ʻana i ka hoʻokomo ʻana i nā lāʻau lapaʻau HER2 i hoʻopaʻa ʻia ma mua i ka hoʻolālā hoʻokele maʻi hiki ke hoʻomaikaʻi i ke ola ʻole o ka maʻi (DFS) i hana i kahi mākeke nui no nā lāʻau lapaʻau kuhikuhi HER2. I kēia lā, ʻoi aku ka lōʻihi o ka noho ʻana o ka poʻe maʻi maʻi maʻi umauma HER2+ me ko lākou maʻi, mahalo i nā hoʻolālā hoʻokele maʻi me ka hoʻohana ʻana i nā regimens. Wahi a Stats Market Research ke wānana nei ka mākeke HER2+ e ulu i $ 12.1B e 2030, ma kahi Compound Annual Growth Rate (CAGR) o 1.5%. Ua hoʻohui ʻia kahi hōʻike mai Mordor Intelligence e ulu ana ka mākeke maʻi maʻi maʻi maʻi ma kahi CAGR o 8.3% i ka wā wānana, 2022-2027.

Ua ʻōlelo ka hōʻike: "Ma muli o ka laha ʻana o COVID-19, ua kū ka mākeke i kahi hoʻihoʻi iki ma muli o ka lohi ʻana o ka maʻi maʻi, nā hemahema o ka lāʻau lapaʻau, a me ka loaʻa ʻole o nā limahana mālama olakino. No ka laʻana, e like me kahi ʻatikala i paʻi ʻia ma ka JAMA Network i ʻAukake 2020, ua nui ka emi ʻana o ka maʻi maʻi maʻi umauma (e like me 51.8%) ma United States mai Malaki 1, 2020, a hiki i ʻApelila 18, 2020. , ʻo ka lohi o ka hōʻoia ʻana o ka maʻi maʻi umauma ua hoʻopilikia i ka mālama ʻana i ia mea. No laila, ua hoʻopilikia maikaʻi ʻia ka maʻi maʻi COVID-19 i ka mākeke maʻi maʻi maʻi maʻi i kāna hana mua. Eia nō naʻe, manaʻo ʻia e loaʻa ka mākeke i nā makahiki e hiki mai ana ke hoʻomau ʻia ka mālama ʻana i ka honua holoʻokoʻa. ʻO nā hui biotech a me nā lāʻau lapaʻau i nā mākeke i kēia pule he Oncolytics Biotech® Inc., Clovis Oncology, Inc., Belite Bio Inc., Endo International plc, Pfizer Inc.

Ua hoʻomau ka Stats Market Research: "Eia kekahi, ʻo nā mea nui e hoʻoulu ai i ka ulu ʻana o ka mākeke ʻo ka piʻi nui a me ka helu prevalence o ka maʻi maʻi umauma ma ka honua holoʻokoʻa, e hoʻonui ana i ka hoʻopukapuka ʻana i ka noiʻi a me ka hoʻomohala ʻana, a me nā holomua i ka biology cancer a me ka pharmacology e hāpai ana i ka ulu lāʻau. ʻO ka piʻi kiʻekiʻe a me ka prevalence rate o ka maʻi maʻi umauma ma ka honua holoʻokoʻa ke kumu nui e alakaʻi nei i ka ulu ʻana o ka mākeke. I loko o ʻAmelika ʻAmelika, manaʻo ʻia ʻo ʻAmelika e hoʻomalu i ka mākeke holoʻokoʻa i ka wā wānana. ʻO nā kumu nui e hoʻoulu ai i ka ulu ʻana o ka mākeke ʻo ka piʻi nui ʻana o ka maʻi kanesa o ka umauma ma ka ʻāina a me ka piʻi ʻana o ka ʻike e pili ana i ka maʻi kanesa a me ka piʻi ʻana o nā huahana.

Hōʻike ʻo Oncolytics Biotech® a me SOLTI i ka ʻikepili Biomarker Clinical hou e hōʻike ana i ka hiki o Pelareorep e hoʻomaikaʻi i ka wānana o nā maʻi maʻi maʻi maʻi ma ka ESMO Breast Cancer Meeting - Oncolytics Biotech® a me SOLTI-Innovative Cancer Research i kēia lā i hoʻolaha i ka ʻikepili biomarker clinical hou e hōʻike ana i nā hopena immunotherapeutic o pelareorep, synergy. ka hoʻopaʻa ʻana, a me ka hiki ke hoʻomaikaʻi i ka nānā ʻana no nā poʻe maʻi me HR +/HER2- maʻi maʻi umauma. ʻO ka ʻikepili, i hōʻike ʻia ma kahi hōʻike pepa ma ka 2022 European Society for Medical Oncology (ESMO) Breast Cancer Meeting, mai nā cohorts 1 a me 2 o ka AWARE-1 window-of-opportunity study i nā maʻi maʻi maʻi umauma mua.

Ua mālama ʻia nā poʻe maʻi ma nā hui mua ʻelua o AWARE-1 me ka pelareorep a me ka aromatase inhibitor letrozole me ka ʻole (cohort 1), a i ʻole me (cohort 2), ka PD-L1 checkpoint inhibitor atezolizumab ma kahi o 21 mau lā ma mua o ka ʻoki ʻana i ko lākou mau maʻi koko. ʻO nā hui 1 a me 2 o AWARE-1 i hoʻopaʻa inoa wale ʻia i nā poʻe maʻi me ka maʻi HR +/HER2-, ka subtype maʻi maʻi umauma a Oncolytics i manaʻo e nānā i kahi noiʻi hoʻopaʻa inoa e hiki mai ana. Ua hōʻike ʻia nā hopena i hōʻike mua ʻia ua hui ʻo AWARE-1 i kāna kumu unuhi unuhi mua, me ka cohort 2 e hoʻokō nei i nā pae hoʻokō i hoʻopaʻa mua ʻia no ka piʻi ʻana o ka mālama ʻana i ka helu CelTIL (ka loulou i ka PR). ʻO ka helu CelTIL kahi metric no ka ʻaʻa ʻana o ka maʻi maʻi a me ka cellularity a pili pū me nā hopena lapaʻau maikaʻi i nā maʻi maʻi maʻi umauma.

"ʻO ka ʻikepili hou loa mai AWARE-1 ke hōʻike hou aku nei i ka hiki o ka pelareorep ke hoʻomaikaʻi i nā hopena lapaʻau i nā maʻi maʻi maʻi maʻi maʻi ma o kona hiki ke hoʻōla i nā cell T a hoʻoponopono hou i ka microenvironment tumor," wahi a Thomas Heineman, MD, Ph.D., Luna Lapaʻau Nui o Oncolytics . "ʻO ka mea nui, ua hoʻonui ka mālama ʻana i ka pelareorep i nā hōʻailona o ka make cell tumor a, ʻoi aku ka maikaʻi o ka 100% o nā mea maʻi i mālama ʻia i ka pelareorep i loaʻa i kahi Risk of Recurrence Score (ROR-S) i hoʻohālikelike ʻia me 55% ma ka baseline. ʻO ka hui pū ʻana, ua hoʻokumu hou kēia mau hopena AWARE-1 i ka hiki i ka pelareorep ke hoʻouka i nā maʻi maʻi ma o nā hana he nui.

He aha e lawe ʻia mai kēia ʻatikala:

The data, which are featured in a poster presentation at the 2022 European Society for Medical Oncology (ESMO) Breast Cancer Meeting, are from cohorts 1 and 2 of the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
The major factors fueling the market growth are the increasing burden of breast cancer in the country and rising awareness pertaining to breast cancer as well as rising product launches.
“Further, the major factors fueling the market’s growth are the high incidence and prevalence rate of breast cancer worldwide, increasing investment in research and development, and advancements in cancer biology and pharmacology promoting drug development.